EUVIMEDEUVIMED entdecken
Crossref

Dendrimer-Mediated Delivery Enhances Therapeutic Efficacy in Triple-Negative Breast Cancer

Anunay James Pulukuri, Anubhav Dhull, Aqib Iqbal Dar, Anu Rani, Rishi Sharma, Clifford E Berkman iD, Anjali Sharma iD

Biomacromolecules · 2025

DOI: 10.1021/acs.biomac.5c00917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, 2025. Verfasst von Anunay James Pulukuri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Arts and Sciences, Washington State University, 1470 NE College Avenue, Pullman, Washington 99164, United States. Hauptthemen laut MEDLINE: Dendrimers, Triple Negative Breast Neoplasms, Camptothecin, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) remains one of the most aggressive and treatment-resistant breast cancer subtypes due to poor drug bioavailability, systemic toxicity, and rapid resistance development. Camptothecin (Campto), a potent topoisomerase I inhibitor, has shown strong anticancer activity but suffers from poor solubility, instability, and off-target toxicity. Here, we report the synthesis and in vitro mechanistic evaluation of a novel dendrimer-drug conjugate, PD-Campto, composed of a generation 4 hydroxyl-terminated PAMAM dendrimer (PD) covalently linked to Campto via biodegradable ester linkers using copper(I)-catalyzed alkyne-azide click (CuAAC) chemistry. PD-Campto demonstrated enhanced aqueous solubility, sustained release in tumor-relevant environments, and significant TNBC cellular uptake. In vitro studies showed significantly higher cytotoxicity, ROS generation, mitochondrial membrane depolarization, caspase-3/7 activation, and apoptosis compared to free Campto. PD-Campto modulated immune checkpoint and cancer stem-like cell markers and showed synergy with the PARP inhibitor Olaparib. These findings suggest PD-Campto is a promising nanotherapeutic for improving TNBC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DendrimersTriple Negative Breast NeoplasmsCamptothecinAntineoplastic AgentsDrug Delivery SystemsHumansFemaleCell Line, TumorApoptosis

Substanzen

DendrimersCamptothecinPAMAM StarburstAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, College of Arts and Sciences, Washington State University, 1470 NE College Avenue, Pullman, Washington 99164, United States.

ORCID-Profile: Clifford E Berkman, Anjali Sharma

Zitieren

APA

Pulukuri, A. J., Dhull, A., Dar, A. I., Rani, A., Sharma, R., Berkman, C. E., & Sharma, A. (2025). Dendrimer-Mediated Delivery Enhances Therapeutic Efficacy in Triple-Negative Breast Cancer. Biomacromolecules. https://doi.org/10.1021/acs.biomac.5c00917

Vancouver

Pulukuri AJ, Dhull A, Dar AI, Rani A, Sharma R, Berkman CE, et al. Dendrimer-Mediated Delivery Enhances Therapeutic Efficacy in Triple-Negative Breast Cancer. Biomacromolecules. 2025. doi:10.1021/acs.biomac.5c00917

BibTeX
@article{Pulukuri2025,
  author = {Pulukuri, Anunay James and Dhull, Anubhav and Dar, Aqib Iqbal and Rani, Anu and Sharma, Rishi and Berkman, Clifford E and Sharma, Anjali},
  title = {Dendrimer-Mediated Delivery Enhances Therapeutic Efficacy in Triple-Negative Breast Cancer},
  journal = {Biomacromolecules},
  year = {2025},
  doi = {10.1021/acs.biomac.5c00917}
}
Kostenlos starten →